Investor Overview

Stock Information
Loading data...
Press Releases
Jan 12, 2022

Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related...

Jan 4, 2022

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10...

Dec 16, 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of...

Dec 9, 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced bullish expectations for prescription and net revenue growth in the fourth quarter of 2021. Total monthly prescriptions (TRx) of Phexxi®...

Dec 8, 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to adjourn, without conducting any business, its 2021 special meeting of stockholders (the "Special Meeting") scheduled to...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The Company is evaluating its investigational drug candidate EVO100 for the prevention of urogenital chlamydia and gonorrhea in women in a pivotal Phase 3 clinical trial, EVOGUARD. Top-line results are expected in the second half of 2022. Positive outcomes could support submission to the FDA for these potential indications in the first quarter of 2023, with an anticipated PDUFA date in the second half of 2023 due to the expedited review afforded by the Fast Track designations was granted for these indications.

The addressable U.S. market opportunity for these current and investigational indications is estimated at $3.6 - $4.5 billion in aggregate.  

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. Discussions are underway with potential licensees for commercialization of Phexxi in multiple international markets.

Latest Financial Results

Q2 2021, Ended June 30, 2021

Earnings Release
Earnings Call
10-Q Filing